Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

News SummaryMost relevantAll newsSector newsTweets

US Judge Upholds Validity Of Merck's Vytorin Patent

share with twitter share with LinkedIn share with facebook
share via e-mail
04/28/2012 | 12:29am CEST

--Judge rules U.S. patent for Vytorin and Zetia is valid and enforceable

--Mylan had challenged patent in bid to sell generic Vytorin and Zetia

--Merck patent due to expire in April 2017

(Adds statement from Merck, additional details.)

   By Peter Loftus 

A federal judge has upheld the validity of a U.S. patent covering Merck & Co.'s (>> Merck & Co., Inc.) cholesterol-lowering drugs Vytorin and Zetia, which could stave off competing generic copies for several years.

In an opinion released Friday, U.S. District Judge Jose Linares in federal court in Newark, N.J., said the patent for was valid and enforceable. The patent covers ezetimibe, an active ingredient in both Zetia and Vytorin.

Merck, based in Whitehouse Station, N.J., said the U.S. patent for Vytorin and Zetia is due to expire in April 2017.

"The court appropriately ruled that the patent for Zetia and Vytorin in the U.S. is valid and enforceable," Bruce N. Kuhlik, executive vice president and general counsel of Merck, said in a press release.

Mylan Inc. (MYL) had applied for U.S. Food and Drug Administration approval to sell generic versions of Vytorin and Zetia before the patent expired, arguing that the patent was invalid and unenforceable.

Merck filed a patent-infringement lawsuit against Mylan in late 2009, seeking to block Mylan's plan to sell generic Vytorin, and in 2010 sued to block Mylan from selling generic Zetia. A trial was held in December 2011, leading to Judge Linares's opinion Friday.

Merck said the court also issued an injunction blocking the approval of Mylan's generic versions until the expiration of the patent.

A Mylan spokeswoman couldn't immediately be reached for comment.

Earlier Friday, Merck reported first-quarter Vytorin sales of $444 million and Zetia sales of $614 million.

Merck previously reached a settlement of patent litigation for Zetia with generics manufacturer Glenmark Pharmaceuticals. The pact will allow Glenmark to sell generic Zetia in December 2016, subject to final regulatory approval.

-By Peter Loftus, Dow Jones Newswires; 215-982-5581; peter.loftus@dowjones.com

Stocks mentioned in the article : Merck & Co., Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK AND COMPANY
01:32p MERCK AND : European Medicines Agency’s CHMP Recommends Approval for Merck..
01:08p Merck, Pfizer Collaborate With Corning
07/20 MERCK AND : Pfizer Collaborate with Corning to Modernize Pharmaceutical Glass Pa..
07/20 Merck and Pfizer Collaborate with Corning to Modernize Pharmaceutical Glass ..
07/20 MERCK : Announces U.S. FDA Grants Tentative Approval for LUSDUNA™ Nexvue&t..
07/18 COMPANHIA BRASILEIRA DE DISTRIBUICAO : (CBD) EPS Estimated At $0.06, Merck & Com..
07/17 MERCK : Announces Presentations of Clinical and Real-World Data at The Alzheimer..
07/12 NETSCIENTIFIC : portfolio company in cancer clinical trial with US drugs giant M..
07/11 MERCK AND : Global Biologic Response Modifiers Sales Market 2017 by top Players ..
07/11 NETSCIENTIFIC : Portfolio Firm Inks Clinical Trial Agreement With Merck
More news
News from SeekingAlpha
07:04a WALL STREET BREAKFAST : Confidence In Bitcoin Is Back
07/20 Gilead Has Another Ace Up Its Sleeve
07/20 Big Pharma and Corning lead initiative to manufacture pharmaceutical glass in..
07/20 FDA tentatively OKs Merck's biologic basal insulin
07/18 Chaos At AstraZeneca
Financials ($)
Sales 2017 40 068 M
EBIT 2017 13 716 M
Net income 2017 7 101 M
Debt 2017 5 068 M
Yield 2017 2,98%
P/E ratio 2017 23,41
P/E ratio 2018 18,23
EV / Sales 2017 4,42x
EV / Sales 2018 4,26x
Capitalization 172 151 M
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 69,7 $
Spread / Average Target 11%
EPS Revisions
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON17.36%367 897
NOVARTIS9.58%222 704
ROCHE HOLDING LTD.4.94%222 036
PFIZER3.26%199 735
SANOFI7.63%121 388